US Edition
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD, says GlobalData - GlobalData
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD: GlobalData - Express Pharma
Tezepelumab, a thymic stromal lymphopoietin (TSLP) inhibitor developed by AstraZeneca and Amgen, demonstrated significant reductions in chronic obstructive pulmonary disease (COPD) exacerbations among eosinophilic subgroups, regardless of chronic bronchitis status, according to new post hoc findings presented at the 2025 American Thoracic Society (ATS) International Conference. These results further support the potential for biomarker-driven bio…
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD, says GlobalData - GlobalData
Tezepelumab, a thymic stromal lymphopoietin (TSLP) inhibitor developed by AstraZeneca and Amgen, demonstrated significant reductions in chronic obstructive pulmonary disease (COPD) exacerbations among eosinophilic subgroups, regardless of chronic bronchitis status, according to new post hoc findings presented at the 2025 American Thoracic Society (ATS) International Conference. These results further support the potential for biomarker-driven bio…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
